Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IRWD - Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A


IEX Last Trade
5.05
-0.060   -1.188%

Share volume: 1,325,722
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$5.11
-0.06
-1.17%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
63%
Profitability 98%
Dept financing 31%
Liquidity 31%
Performance 44%
Company vs Stock growth
vs
Performance
5 Days
1.61%
1 Month
-27.09%
3 Months
-16.50%
6 Months
-66.53%
1 Year
-44.64%
2 Year
-53.41%
Key data
Stock price
$5.05
P/E Ratio 
87.74
DAY RANGE
N/A - N/A
EPS 
$0.06
52 WEEK RANGE
$3.79 - $15.70
52 WEEK CHANGE
-$0.45
MARKET CAP 
808.279 M
YIELD 
N/A
SHARES OUTSTANDING 
159.739 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.10
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,520,530
AVERAGE 30 VOLUME 
$2,433,807
Company detail
CEO: Mark Mallon
Region: US
Website: https://www.ironwoodpharma.com/
Employees: 533
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b

Recent news